Virus-mimetic Fusogenic Nanovesicles (FuNvs) Technology based In Vivo CAR-T Development

Q: What are the advantages of in vivo CAR-T cell production by FuNVs technology comparing traditional methods?

In vivo CAR-T cell production using FuNVs bypasses the need for complex and costly ex vivo processing. This simplifies the manufacturing process, reduces treatment costs, and makes CAR-T therapy more accessible. Additionally, the in vivo approach mitigates risks associated with CRS and genomic integration, enhancing patient safety.

Online Inquiry

Chimeric Antigen Receptor (CAR)-T cell therapy represents a revolutionary approach in the treatment of certain types of cancers, most notably B-cell malignancies. Traditional CAR-T cell therapies have demonstrated high efficacy but have been hampered by complex and costly ex vivo cell manipulation processes. At Creative Biolabs, we have developed an innovative approach to overcome these challenges through the use of virus-mimetic fusogenic nanovesicles (FuNVs) technology. This novel method facilitates the in vivo CAR-T cell development, thereby simplifying the treatment process and expanding its applicability.

Introduction of Virus-mimetic Fusogenic Nanovesicles Technology

FuNVs are lipid-based nanoparticles that mimic the behavior of viruses in terms of their ability to fuse with target cell membranes. This fusion capability allows for the direct delivery of therapeutic proteins or nucleic acids into the target cells. At Creative Biolabs, FuNVs are engineered by modifying their surface with fusogenic proteins derived from viruses such as measles virus or reovirus. Specifically, the inclusion of single-chain variable fragments (scFv) that recognize cell-specific markers like CD3 on T-cells adds precision to the targeting and delivery mechanism.

These modifications enable FuNVs to bind specifically to T-cells and mediate the direct insertion of CAR proteins into the T-cell membrane, converting them into CAR-T cells in vivo. This technology represents a significant advancement in simplifying the generation of CAR-T cells and has the potential to mitigate risks associated with traditional ex vivo processes, such as cytokine release syndrome (CRS) and random viral integration.

Our In Vivo CAR-T Development Services Using Virus-mimetic Fusogenic Nanovesicles Technology

At Creative Biolabs, we have pioneered the use of FuNVs to empower in vivo CAR-T development services.

Construction of CAR-FuNVs

Our services involve the design and construction of CAR-FuNVs that carry both T-cell fusogens and CAR proteins. The fusogens ensure the targeted fusion of the nanovesicles with T-cells, while the CAR proteins are inserted directly into the T-cell membranes. The production process involves the isolation of FuNVs from the producer cells through a series of washing and centrifugation steps to ensure purity and functional integrity. The resulting FuNVs were characterized to ensure the correct size, zeta potential, and surface protein expression.

In Vivo Validation

The in vivo experiments demonstrated the efficiency of the FuNVs in delivering CAR proteins to T-cells. We established a variety of animal models and relevant in vivo experimental designs to verify the effectiveness of this technique, as well as to verify the potent anti-tumor activity of CAR molecules. In addition, we also provide relevant animal model toxicity assessments to assess whether this technique mediates a strong toxic effect.

Highlights of Our Virus-mimetic Fusogenic Nanovesicles Technology

Specificity and Efficiency

The key feature of our FuNV technology lies in its specificity and efficiency. The use of scFv to target CD3 ensures that the fusogenic activity is directed specifically towards T-cells, minimizing off-target effects. This specificity is crucial for the safe and effective generation of CAR-T cells in vivo.

Transient CAR Expression

Unlike traditional approaches that integrate CAR genes into the T-cell genome, the FuNV approach results in transient expression of the CAR protein. This is advantageous as it reduces the risk of prolonged T-cell activation, which is a common cause of adverse effects such as CRS. The temporary nature of CAR expression ensures that the therapeutic effects are maintained without long-term safety concerns.

Biocompatibility

The use of cell-derived nanovesicles ensures high biocompatibility, reducing the likelihood of immune reactions or toxicity. Furthermore, the incorporation of naturally occurring proteins like CD47 helps evade phagocytosis, thereby prolonging the circulation time of FuNVs and enhancing their therapeutic efficacy.

Frequently Asked Questions

Q1: What are the advantages of in vivo CAR-T cell production by FuNVs technology comparing traditional methods?

A1: In vivo CAR-T cell production using FuNVs bypasses the need for complex and costly ex vivo processing. This simplifies the manufacturing process, reduces treatment costs, and makes CAR-T therapy more accessible. Additionally, the in vivo approach mitigates risks associated with CRS and genomic integration, enhancing patient safety.

Q2: Are there any long-term safety concerns with FuNVs?

A2: The transient nature of CAR protein expression reduces long-term safety risks, including the development of CRS and potential genomic alterations. Moreover, FuNVs derived from macrophages exhibit high biocompatibility and low immunogenicity, further minimizing potential adverse effects.

Q3: Can this technology be adapted for other types of CARs or target cells?

A3: Absolutely. The versatility of FuNVs allows for the incorporation of different fusogens and scFvs to target various cell types and deliver a range of therapeutic proteins. This adaptability makes the technology applicable to diverse therapeutic areas beyond oncology, including autoimmunity and infectious diseases.

Creative Biolabs' innovative use of virus-mimetic fusogenic nanovesicles assists in global customers' CAR-T development. By facilitating the in vivo production of CAR-T cells, FuNVs simplify the treatment process, enhance safety, and broaden the therapeutic potential of CAR-T technology. If you are interested in our virus-mimetic fusogenic nanovesicle technology, please feel free to contact us directly.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.